Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New ...

With the help of prescription medications and a whole lot of moisturizing, it’s possible to keep dermatitis under control.

The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the signaling of interleukin (IL)-31.

Jason B. Pieper, DVM, MS, DACVD, talks about the multiple therapies available for cases of moderate and severe atopic dermatitis and delves into each option ...

Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha ...

The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate ...

Opzelura is a treatment for nonsegmental vitiligo in patients 12 and older, making it the first and only cream in the U.S.

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...

Jason B. Pieper, DVM, MS, DACVD: …It is tough when we talk about atopic dermatitis, I mean, there's a variety [of causes].

UK MHRA grants marketing approval to Galderma’s nemolizumab to treat prurigo nodularis and atopic dermatitis: United Kingdom Tuesday, February 18, 2025, 14:00 Hrs [IST] The Medi ...